Drug Trial Radar · NCT02117115
Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Last checked: Nov 20, 2026Latest source record: Jun 11, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Jun 2014
Primary completion
Oct 2014
Study completion May 2015
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 17, 2014
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Screening
- Who can join
- All sexes, from 20 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Contrast-enhanced abdominal CT will be performed 1-2 weeks after allogeneic stem cell transplant, and radiographic evidence of mucosal inflammation will be correlated with the subsequent development of acute graft versus host disease. The primary endpoint is the feasibility and safety of contrast-enhanced abdominal CT in the early post-transplant period, as defined by the risk of contrast-related nephropathy or allergic reaction.
Conditions
- Myelodysplastic Syndromes
- Leukemia, Myeloid, Acute
- Leukemia, Myelogenous, Chronic
- Multiple Myeloma
Interventions
Dynamic contrast-enhanced computed tomographyRadiation
CT scan performed between Day +7 and Day +14.
IoversolDrug
To optimize visualization of bowel mucosal, patient will be given 1350 ml, or as much as can be tolerated, of negative oral contrast to distend the small bowel one hour prior to scanning. A weight-based volume of Optiray-350 will be injected at a rate of 4 cc/sec followed by 50 cc of saline flush also at 4 cc/sec.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of contrast related nephropathyTime frame: Baseline through 72 hours after intravenous contrast administration
- Incidence of contrast allergic reactionTime frame: Within 4 hours after contrast administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Washington University School of Medicine
St Louis, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.